Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Uncategorized
Uncategorized
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational...
atai Life Sciences to Participate in Upcoming June Investor Conferences
atai Life Sciences Announces First Subject Dosed in the Phase 1...
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial...
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces...
atai Life Sciences to Participate in Upcoming May Investor Conference
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late...
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
atai Life Sciences to Participate in the Cowen 43rd Annual Health...
Expanding ketamine’s horizons for rare neurological disorders
1
2
3
...
12
Page 1 of 12